The prognosis of acute adult T-cell leukemia lymphoma (ATL), a malignancy related to human T-cell leukemia virus type 1 (HTLV-1), is poor with a median survival time of 6 months. Encouraging results have been reported with the combination of interferon alpha (IFN-) and zidovudine (AZT.) The provider referenced a study of the combination that also included arsenic tioxide.
In regard to interferon itself, there are a number of phase II studies. There are also studies with zidovudine or arsenic tri-oxide. Arsenic has been reported to be effective by itself in T-cell leukemia/ lymphoma while interferon may be adding to virus supression.
There are a range of case reports, series and phase II studies and no current trials of this combinaiton is listed by clinicaltrials.com. I consider interferon to be suppported.
Tamura Therapeutic potential of arsenic trioxide with or without interferon- for relapsed/refractory adult T-cell leukemia/lymphoma
Haematologica 2007 92: 719-720.
G. Kchour, M. Tarhini, M.-M. Kooshyar, H. El Hajj, E. Wattel, M. Mahmoudi, H. Hatoum, H. Rahimi, M. Maleki, H. Rafatpanah, et al.
Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL)Blood, June 25, 2009; 113(26): 6528 – 6532.
Hermine O, Dombret H, Poupon J, Arnulf B, Lefrere F, Rousselot P, et al. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol J 2004;5:130-4.
K. Tsukasaki, O. Hermine, A. Bazarbachi, L. Ratner, J. C. Ramos, W. Harrington Jr, D. O’Mahony, J. E. Janik, A. L. Bittencourt, G. P. Taylor, et al. Definition, Prognostic Factors, Treatment, and Response Criteria of Adult T-Cell Leukemia-Lymphoma: A Proposal From an International Consensus Meeting J. Clin. Oncol., January 20, 2009; 27(3): 453 – 459.